Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
Lantern Pharma (NASDAQ:LTRN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely [Yahoo! Finance]
Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates [Yahoo! Finance]